These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 31463605)
21. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. Ko MC; Husbands SM Handb Exp Pharmacol; 2022; 271():435-452. PubMed ID: 33274403 [TBL] [Abstract][Full Text] [Related]
22. Endogenous Opioid Dynorphin Is a Potential Link between Traumatic Brain Injury, Chronic Pain, and Substance Use Disorder. Best KM; Mojena MM; Barr GA; Schmidt HD; Cohen AS J Neurotrauma; 2022 Jan; 39(1-2):1-19. PubMed ID: 34751584 [TBL] [Abstract][Full Text] [Related]
23. Development of κ opioid receptor antagonists. Carroll FI; Carlezon WA J Med Chem; 2013 Mar; 56(6):2178-95. PubMed ID: 23360448 [TBL] [Abstract][Full Text] [Related]
24. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Jackson KJ; Jackson A; Carroll FI; Damaj MI Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637 [TBL] [Abstract][Full Text] [Related]
25. Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry. Tejeda HA; Wang H; Flores RJ; Yarur HE Handb Exp Pharmacol; 2022; 271():223-253. PubMed ID: 33580392 [TBL] [Abstract][Full Text] [Related]
27. Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography. Placzek MS Handb Exp Pharmacol; 2022; 271():547-577. PubMed ID: 34363128 [TBL] [Abstract][Full Text] [Related]
28. Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors. Kissler JL; Walker BM Neuropsychopharmacology; 2016 Jan; 41(2):560-7. PubMed ID: 26105136 [TBL] [Abstract][Full Text] [Related]
29. Role of kappa-opioid receptors in stress and anxiety-related behavior. Van't Veer A; Carlezon WA Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029 [TBL] [Abstract][Full Text] [Related]
30. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Jackson KJ; Carroll FI; Negus SS; Damaj MI Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057 [TBL] [Abstract][Full Text] [Related]
31. "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats". Valenza M; Butelman ER; Kreek MJ Psychopharmacology (Berl); 2017 Aug; 234(15):2219-2231. PubMed ID: 28550455 [TBL] [Abstract][Full Text] [Related]
32. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice. Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819 [TBL] [Abstract][Full Text] [Related]
33. Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development. Negus SS; Banks ML Pharmacol Biochem Behav; 2018 Jan; 164():32-39. PubMed ID: 28442370 [TBL] [Abstract][Full Text] [Related]
34. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. Xu M; Petraschka M; McLaughlin JP; Westenbroek RE; Caron MG; Lefkowitz RJ; Czyzyk TA; Pintar JE; Terman GW; Chavkin C J Neurosci; 2004 May; 24(19):4576-84. PubMed ID: 15140929 [TBL] [Abstract][Full Text] [Related]
35. KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway. Estave PM; Spodnick MB; Karkhanis AN Handb Exp Pharmacol; 2022; 271():351-377. PubMed ID: 33301050 [TBL] [Abstract][Full Text] [Related]
36. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659 [TBL] [Abstract][Full Text] [Related]
37. Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder. Ragu Varman D; Jayanthi LD; Ramamoorthy S Handb Exp Pharmacol; 2022; 271():97-112. PubMed ID: 34136961 [TBL] [Abstract][Full Text] [Related]
38. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Tejeda HA; Chefer VI; Zapata A; Shippenberg TS Psychopharmacology (Berl); 2010 Jun; 210(2):231-40. PubMed ID: 20232058 [TBL] [Abstract][Full Text] [Related]
39. Kappa opioid receptors mediate yohimbine-induced increases in impulsivity in the 5-choice serial reaction time task. Funk D; Tamadon S; Coen K; Fletcher PJ; Lê AD Behav Brain Res; 2019 Feb; 359():258-265. PubMed ID: 30414973 [TBL] [Abstract][Full Text] [Related]
40. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]